Clinical Trial Update: A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 dose-determination and safety study of X4P-001 (mavorixafor) in WHIM syndrome has completed, with results posted in 2024 describing dose optimization …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Whim Syndrome

Drugs mentioned

• X4P-001 (Mavorixafor) (mavorixafor)

Snippet

Sponsor: X4 Pharmaceuticals | Conditions: WHIM Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2024-10-30